While CAR-T therapies could vastly improve outcomes in some types of blood cancer, finding ways to replicate this effectively and safely in solid tumours remains a challenge.
Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago.
UK diagnostics company Owlstone Medical was among winners of a $1 million award that will help develop new devices for patients with idiopathic pulmonary fibrosis (IPF).
